On May 7, PIPC submitted comments on the Institute for Clinical and Economic Review's (ICER) assessment of chronic obstructive pulmonary disease (COPD).
The letter criticizes ICER for using data sources that do not accurately capture the reality for COPD patients in the U.S. ICER also continues to use the discriminatory QALY and also fails to capture the heterogenous nature of COPD in its assessment.
"If ICER is to take seriously its role of informing health policy decision makers about the value of new therapies, it needs to move away from the assumption that all patients are the same," wrote PIPC Chairman Tony Coelho. "...It is important that ICER accurately capture the value of new treatments, as segments of the patient population still desperately need new options."
"If ICER is to take seriously its role of informing health policy decision makers about the value of new therapies, it needs to move away from the assumption that all patients are the same," wrote PIPC Chairman Tony Coelho. "...It is important that ICER accurately capture the value of new treatments, as segments of the patient population still desperately need new options."
| pipc_copd_icer_final.pdf |
